1. Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25(12):1325–34.
2. Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363–72.
3. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015.
http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
. Accessed 5 Sep 2016.
4. European Medicines Agency (EMA). Guideline on similar biological medicinal products. 2014.
http://www.ema.europaeu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
. Accessed 5 Sep 2015.
5. Australian Therapeutic Goods Administration (TGA). Regulation of biosimilar medicines (Version 2.0, December 2015).
https://www.tga.gov.au/sites/default/files/evaluation-biosimilars-151217_0.pdf
. Accessed 5 Sep 2016.